Identification of PRMT5 as a therapeutic target in cholangiocarcinoma

To cite: Elurbide J, Colyn L, Latasa MU, et al. Identification of PRMT5 as a therapeutic target in cholangiocarcinoma. Gut 2025;74:116-127.
Read the full article here:doi.org/10.113...
Objective: We characterised the enzyme protein arginine-methyltransferase 5 (PRMT5) as a novel therapeutic target in CCA.
Conclusion: PRMT5 and MEP50 are frequently upregulated in human CCA, and PRMT5-targeting drugs have significant antitumoural efficacy in clinically relevant CCA models. Our findings support the evaluation of PRMT5 inhibitors in clinical trials, including their combination with cytotoxic and immune therapies.